A single vaccine for influenza and pneumonia. Influenza and bacterial pneumonia collaborate to kill millions of people each year. This project aims to develop a single vaccine that will provide long-lasting protection against both influenza and pneumonia.
Improved methods for quantitation of acute phase proteins in biological samples. Using monoclonal antibodies and fluorescence polarisation, we aim to develop improved quantitative analytical methods that are superior to the current clinical assays. The initial targets will be C-reactive protein (CRP) and serum amyloid precursor protein (SAP), but the technology should be readily adaptable to other serum proteins. Better assays for CRP and SAP will greatly facilitate improved clinical management ....Improved methods for quantitation of acute phase proteins in biological samples. Using monoclonal antibodies and fluorescence polarisation, we aim to develop improved quantitative analytical methods that are superior to the current clinical assays. The initial targets will be C-reactive protein (CRP) and serum amyloid precursor protein (SAP), but the technology should be readily adaptable to other serum proteins. Better assays for CRP and SAP will greatly facilitate improved clinical management of those at risk of heart attack, the single biggest contributor to healthcare costs in Australia. We further aim to adapt this technology to enable "point-of-care" assays that would help medical practitioners, especially in rural areas, to make informed diagnoses immediately.Read moreRead less
Imaging Mass Spectrometry (IMS), a peptide biomarker discovery tool using tissue. Cancer is the second most common cause of death in Australia. The newly developed technology of Imaging Mass Spectrometry for peptides in tissue has the potential to discover biomarkers for early diagnosis of cancer. This new technology could avoid a number of cancer deaths and reduce suffering of patients through earlier and better diagnosis.
Long Chain Omega-3 Polyunsaturated Fatty Acids and Heart Health in Humans. The primary aims of the project is to assess the effect of DHA rich tuna oil on cholesterol carrying lipoproteins and to determine a quicker method in assessing someone's omega-3 status. The expected outcomes include the determination of: 1) the most appropriate blood sample and a rapid test and for evaluating the omega-3 status; 2) the minimum dose of tuna oil required which will not only improve a person's omega-3 statu ....Long Chain Omega-3 Polyunsaturated Fatty Acids and Heart Health in Humans. The primary aims of the project is to assess the effect of DHA rich tuna oil on cholesterol carrying lipoproteins and to determine a quicker method in assessing someone's omega-3 status. The expected outcomes include the determination of: 1) the most appropriate blood sample and a rapid test and for evaluating the omega-3 status; 2) the minimum dose of tuna oil required which will not only improve a person's omega-3 status but also improve their plasma lipid profile and hence reduce their overall risk for cardiovascular disease (CVD); and 3) the use of the Omega-3 Index by medical practitioners. The significance is the increased knowledge of the health benefits of DHA rich tuna oil and that a new CVD risk marker will be generally accepted.Read moreRead less
Nanosampling sensors for real-time embryo monitoring. The health potential of every individual is established early in life, during the period when the oocytes mature and embryos are formed. This project will develop a photonic sensing platform capable of monitoring embryos as they develop, which will lead to new insight into the earliest stages of life and improved assisted reproduction technologies.
Drug Targeting to Immune Cells Using Modified Inulin Particles. Vaxine Pty Ltd is an Australian biotechnology company that has discovered specific particulate forms of inulin that are efficiently internalised by human immune cells. This project aims to exploit cell migration to injury and infection sites by attaching drugs to inulin particles creating a targeted drug delivery system. This system will transport drugs specifically to afflicted areas, reducing systemic concentrations of drugs and h ....Drug Targeting to Immune Cells Using Modified Inulin Particles. Vaxine Pty Ltd is an Australian biotechnology company that has discovered specific particulate forms of inulin that are efficiently internalised by human immune cells. This project aims to exploit cell migration to injury and infection sites by attaching drugs to inulin particles creating a targeted drug delivery system. This system will transport drugs specifically to afflicted areas, reducing systemic concentrations of drugs and hence the risks of dose related side effects. This project has potential both to improve healthcare and to encourage the growth of expertise in the biotechnology industry in Australia.Read moreRead less
Electrochemical biosensors for detection of cardiac disease markers in blood. Cardiovascular diseases leading to heart failure have a prevalence of over 16 per cent in Australia. The social, economic and health burden is higher than for any other disease group. Hence, it is critically important to develop fit-for-purpose sensors of known cardiac biomarkers, which alert patients and clinicians of the risk of imminent heart failure.
Novel biodiagnostic platforms for human metabolites. The innovative biosensor technologies developed in this project will be utilised at first by Australian athletes, enabling them to better monitor physiological conditions during training and thereby help maintain international competitiveness. Real-time sensing of lactate and other metabolites in athletes using advanced biomaterials coupled to frontier telemetry protocols for remote sensing will be extendable to bio-diagnostic needs in human h ....Novel biodiagnostic platforms for human metabolites. The innovative biosensor technologies developed in this project will be utilised at first by Australian athletes, enabling them to better monitor physiological conditions during training and thereby help maintain international competitiveness. Real-time sensing of lactate and other metabolites in athletes using advanced biomaterials coupled to frontier telemetry protocols for remote sensing will be extendable to bio-diagnostic needs in human health care and have significant social and economic benefits. Australia's international position in the application of interfacial science and nanomaterials for outcomes in biomedical engineering will be strengthened. Read moreRead less
Development of an implantable device to monitor lactate levels in blood: Monitoring the Performance of Australian athletes using Biosensor Technology. Sport is a critical area for social and economic investments. Novel medical monitoring systems using implantable biosensors will ensure optimal training programs for Australian athletes and maintain international competitiveness. Here we are developing a biosensor for real-time monitoring of lactate levels in athletes using frontier porous semicon ....Development of an implantable device to monitor lactate levels in blood: Monitoring the Performance of Australian athletes using Biosensor Technology. Sport is a critical area for social and economic investments. Novel medical monitoring systems using implantable biosensors will ensure optimal training programs for Australian athletes and maintain international competitiveness. Here we are developing a biosensor for real-time monitoring of lactate levels in athletes using frontier porous semiconductor technology and smart telemetry protocols to transfer the readings to a remote base unit. These highly innovative devices and the materials that they are made from have enormous commercial potential in biomedical engineering. There is a strong potential for Australia to have an important stake in this area by combining expertise in engineering, chemistry and nanostructured materials.Read moreRead less
Bio-MEMS eye sensor for continuous monitoring of intraocular pressure. Glaucoma is a leading cause of preventable blindness, particularly prevalent in the 60+ population, caused by elevated intraocular pressure (IOP). Current treatment to monitor and prevent glaucoma-related blindness is by lowering IOP with eye-drops, laser therapy or surgery. This project directly benefits our aging population by ensuring independence and quality of life, whilst reducing long-term medical and social costs. By ....Bio-MEMS eye sensor for continuous monitoring of intraocular pressure. Glaucoma is a leading cause of preventable blindness, particularly prevalent in the 60+ population, caused by elevated intraocular pressure (IOP). Current treatment to monitor and prevent glaucoma-related blindness is by lowering IOP with eye-drops, laser therapy or surgery. This project directly benefits our aging population by ensuring independence and quality of life, whilst reducing long-term medical and social costs. By incorporating nanotechnology with ophthalmology we will provide an economic solution to long-term, reliable, home-monitoring of IOP. An implantable IOP sensor, will identify patients requiring more invasive treatment compared with those with less aggressive disease, leading to better health resource utilisation.Read moreRead less